Nordic Nanovector NOK0.20
Nordic Nanovector NOK0.20
-6,26 %
30,86 NOK
-2,06
Noter.
30,86
Høy
33,86
Endring
-6,26 %
Lav
30,44
Oppdatert
16.09.2019
Åpen
33,86
Factsheet for Nordic Nanovector NOK0.20
Company Profile
Description
Nordic Nanovector ASA is a biopharmaceutical company. It is engaged in the development and commercialization of targeted therapeutics to improve the lives of patients with haematological cancers, such as non-Hodgkin lymphoma and leukaemia. The company's main clinical stage product is Betalutin. Its product pipeline consists of chimeric, affilutin and NNV003 ARCs product candidates.
Key Stats
Website: http://www.nordicnanovector.com
Headquarter country: Norway
Employees: 14
Market Cap (at close 27.08.2019): NOK 1B
Fiscal Year Ends: desember
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings
Forward Price/Earnings
Price/Free Cash Flow
Return on Assets -53,90 -32,20 -26,10 -31,30 -29,50
Return on Equity -64,80 -36,10 -28,30 -33,20 -31,10
Return on Invested Capital -65,70 -36,80 -28,90 -35,50 -33,40
Dividend


Dividend/Share:
Ex. Dividend Date:01.01.0001
Trailing Dividend Yield:
Payout Ratio:0,00
Date Currency Amount
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 0,00 0,30 0,31 0,44 0,44
Gross Profit -0,22
Gross Margin %
Operating Expenses 2018 2017 2016 2015 2014
EBITDA -338,00 -315,00 -215,00 -182,00 -68,00
Net income -338,00 -294,00 -236,00 -173,00 -64,00
Basic Earnings Per Share -6,86 -5,97 -5,25 -4,27 -2,39
Operating Income -0,34 -0,32 -0,22 -0,18 -0,07
Operating Margin % -104 808,61% -68 905,10% -41 898,17% -15 642,37%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow -327,00 -249,00 -170,00 -150,00 -58,00
Capital Expenditures -2,00 -3,00 -1,00 -2,00 -2,00
Free Cash Flow -329,00 -252,00 -172,00 -152,00 -60,00
Balance Sheet

Assets 31.12.2018 31.12.2017 31.12.2016 31.12.2015 31.12.2014
Current Assets 469,50 776,30 1 041,59 757,56 344,09 85,64
Long Term Assets 4,08 4,17 3,15 2,81 1,62 0,38
Total Assets 473,59 780,47 1 044,74 760,37 345,71 86,02
Liabilities 31.12.2018 31.12.2017 31.12.2016 31.12.2015 31.12.2014
Total Current Liabilities 107,02 97,24 95,45 47,63 15,50 7,24
Long Term Liabilities 0,00 0,00
Total Liabilities 95,45 47,63
Equity 31.12.2018 31.12.2017 31.12.2016 31.12.2015 31.12.2014
Retained Earnings -296,41 -809,64 -514,08 -278,31 -105,20 -41,36
Treasury Stock
Total Stockholder Equity 363,19 679,61 949,29 712,74 330,21 78,79
Net Tangible Assets 363,19 679,59 949,03 712,21 329,79 78,79